Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rVWF · 1 trial · 1 indication
sABR was derived as \[number of treated bleeds\] / \[duration in years\]. Bleeds with unknown causality were considered as spontaneous. Bleeds were categorized based on the investigator assessment of cause. sABR during the first 12 months of prophylactic treatment with rVWF (vonicog alfa) was reported.
| Arm | Type | Description |
|---|---|---|
| On-Demand | EXPERIMENTAL | Participants will receive recombinant von Willebrand factor (rVWF) (with or without ADVATE). |
| Prophylaxis | EXPERIMENTAL | Participants will receive recombinant von Willebrand factor (rVWF). |
| Name | Type | Description |
|---|---|---|
| rVWF | BIOLOGICAL | Recombinant von Willebrand factor |
| rFVIII | BIOLOGICAL | Recombinant Factor VIII |
Inclusion Criteria: The participant will not be considered eligible for the study without meeting all of the criteria below. Participants who have completed Study 071301 or Study 071102 (or participants who have completed the surgery arm treatment in Study 071102 and want to continue to receive on...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Vonicog Alfa, ADVATE |
| Alnylam Pharmaceuticals, Inc | ALNY | 1 | PHASE2 | ALN-6400 |
| Hemab Therapeutics Holdings, Inc. | COAG | 2 | PHASE1 | HMB-002 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | - | Undisclosed |
rVWF is a recombinant von Willebrand factor being studied for the treatment of Von Willebrand Disease (VWD), a bleeding disorder. It is intended for use in pediatric and adult patients with severe VWD. The drug is currently in Phase 3 clinical development and is not yet approved.
rVWF is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical trials to evaluate the safety and efficacy of rVWF in patients with severe Von Willebrand Disease.
rVWF is in Phase 3 clinical development. A Phase 3 study has been completed, but the drug remains investigational and has not received regulatory approval. It is being studied for the treatment of severe Von Willebrand Disease in pediatric and adult patients.
rVWF has one completed Phase 3 clinical trial, identified as NCT03879135. This study evaluated rVWF in pediatric and adult participants with severe Von Willebrand Disease. The trial enrolled 38 participants and was conducted in multiple countries, including the United States, Austria, France, Germany, Italy, Netherlands, Russia, Spain, and Turkey.
Yes, rVWF is the abbreviation for recombinant von Willebrand factor. It is a laboratory-made version of the von Willebrand factor protein, which is deficient or defective in people with Von Willebrand Disease. The drug is being developed to replace this missing protein and help control bleeding.